Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer (WAYWIN-301)

13 novembre 2026 aggiornato da: Wayshine Biopharm, Inc.

An Open-label, Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of WSD0922-FU Monotherapy Versus Platinum-based Doublet Chemotherapy in Participants With EGFR C797S Mutation-positive, Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy.

This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

196

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200123
        • Shanghai East Hospital
        • Contatto:
        • Investigatore principale:
          • Caicun Zhou, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Histologically or cytologically confirmed locally advanced or metastatic NSCLC
  2. Eligible for platinum-based doublet chemotherapy
  3. Prior first-line treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
  4. Tissue sample confirmed C797S positive by central lab using NGS
  5. At least one measurable target lesion per RECIST v1.1 criteria
  6. ECOG 0-1
  7. Adequate organ function and bone marrow function
  8. Women should take appropriate contraceptive measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
  9. Male participants should agree to the use of contraceptive measures

Exclusion Criteria:

  1. Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, HER2 mutations, RET fusion, ROS1 fusion etc.)
  2. Histological or phenotypic transformation
  3. Any severe or uncontrolled systemic disease
  4. ≥ Grade 2 toxicities per CTCAE v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
  5. Participants with leptomeningeal, brainstem, or spinal cord metastases and/or spinal cord compression, as well as active brain metastases, increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
  6. A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring steroid treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
  7. Clinically significant cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
  8. Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
  9. Poorly controlled diabetes mellitus or hypertension
  10. History of other primary malignancies within two years
  11. Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
  12. Active infectious diseases (e.g., active HIV, HBV and HCV)
  13. Known alcohol or drug dependence
  14. Mental disorders or poor compliance
  15. The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: WSD0922-FU Tablet

Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

Altri nomi:
  • WSD0922
Comparatore attivo: Platinum-Based Doublet Chemotherapy

Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance):

Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle.

Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle.

Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

Altri nomi:
  • Cisplatino
  • Carboplatino
  • Pemetrexed
  • Platinum-based doublet chemotherapy

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression Free Survival (PFS)
Lasso di tempo: From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1

From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Survival (OS)
Lasso di tempo: From the date of randomization to the date of death from any cause, assessed up to 36 months.

OS

From the date of randomization to the date of death from any cause, assessed up to 36 months.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
PFS as assessed by investigator per RECIST 1.1
Lasso di tempo: From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Objective Response Rate (ORR)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

ORR as assessed by investigator and BICR per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Duration of Response (DOR)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

DoR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Disease Control Rate (DCR)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

DCR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Time to Disease Progression (TTP)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

TTP by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Time to Response (TTR)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

TTR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial ORR (icORR)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icORR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial PFS (icPFS)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icPFS by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial DOR (icDOR)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icDOR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial DCR (icDCR)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icDCR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial TTP (icTTP)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icTTP by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial TTR (icTTR)
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icTTR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
AE and SAE
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

AE and SAE per CTCAE 6.0

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13
Lasso di tempo: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Caicun Zhou, MD, Shanghai East Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

10 dicembre 2026

Completamento primario (Stimato)

1 maggio 2028

Completamento dello studio (Stimato)

31 ottobre 2029

Date di iscrizione allo studio

Primo inviato

8 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi